FDA Introduces Dietary Supplement Ingredient Directory

Epstein Becker & Green
Contact

Epstein Becker & Green

In a March 6, 2023 constituent update, the U.S. Food and Drug Administration (“FDA”) announced the launch of its new Dietary Supplement Ingredient Directory (the “Directory”), which the agency describes as “a one stop shop of ingredient information that was previously found on different FDA webpages.”  According to the FDA, the Directory is “intended to help manufacturers, retailers, and consumers stay informed about ingredients that may be found in products marketed as dietary supplements and quickly locate information about such ingredients on the FDA’s website.”  With the release of the Directory, the FDA is now retiring the “FDA Dietary Supplement Advisory Ingredient List.” 

As of the date of this post, the Directory includes the following 27 ingredients:

5-Alpha-Hydroxy-Laxogenin DMHA N-acetyl-L-cysteine
Acacia rigidula Ephedrine alkaloids Octopamine
Biotin Higenamine Phenibut
BMPEA Higenamine HCl Picamilon
Cannabidiol Hordenine Pure and Highly Concentrated Caffeine
Cesium chloride Hordenine HCl Pyridoxamine
Comfrey Kava Red yeast rice
DMAA Kratom Tianeptine
DMBA Methylsynephrin Vinpocetine 

The FDA cautions that these are “commonly used names for each ingredient” and that “synonyms or other known names for an ingredient” may not be listed.

Interestingly, the FDA acknowledges that the Directory is not intended to be “a comprehensive list of all ingredients used in products marketed as dietary supplements[.]”  Rather, it appears that the FDA intends to highlight ingredients that the FDA has either addressed in a warning letter or otherwise questioned the use of in dietary supplements.  Indeed, the Directory is, in large part, populated with links to FDA safety communications and warning letters.  It is yet to be seen how plaintiffs’ class action lawyers might attempt to use the Directory; however, the FDA has not stated that the Directory has any particular legal effect.  In fact, the FDA acknowledges that the Directory “may not include all actions the agency has taken with respect to a particular ingredient.” Nevertheless, manufacturers, retailers, and companies marketing dietary supplements should assess whether any of their current or anticipated products contain the ingredients listed on the Directory, and, if so, determine the impact of any FDA-issued guidance concerning such ingredient(s).  EBG will continue to monitor additions and other updates to the Directory.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Epstein Becker & Green | Attorney Advertising

Written by:

Epstein Becker & Green
Contact
more
less

Epstein Becker & Green on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide